Physician profile
Mohammad Ahmed
NPI 1629278312
$4,707.08
in general payments reported to CMS, 2019-2025
36 companies · $1,062 in 2025
The $1,062 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $217 · 2020: $25.22 · 2021: $910 · 2022: $716 · 2023: $928 · 2024: $849 · 2025: $1,062.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,839.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,838.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $545.69 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $506.93 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $492.30 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $484.97 | 2021-2025 | Jardiance |
| Novo Nordisk INC | $438.50 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $224.29 | 2021-2025 | Otezla, Repatha, Repatha |
| Vanda Pharmaceuticals INC. | $217.35 | 2019 | |
| Esperion Therapeutics, INC. | $213.64 | 2021-2025 | Nexletol |
| Bayer Healthcare Pharmaceuticals INC. | $153.81 | 2024-2025 | |
| Abbvie INC. | $151.38 | 2021-2022 | |
| Exact Sciences Corporation | $144.06 | 2023-2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $116.87 | 2022-2025 | Myrbetriq, Veozah |
| Pfizer INC. | $116.46 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $93.03 | 2023 | Rexulti, Abilify Asimtufii |
| Sumitomo Pharma America, INC. | $87.09 | 2024-2025 | Gemtesa |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $83.73 | 2021-2023 | Freestyle Libre 3 |
| Supernus Pharmaceuticals, INC. | $73.84 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $59.45 | 2024 | Voquezna |
| Inspire Medical Systems, INC. | $56.19 | 2024 | Inspire |
| Merck Sharp & Dohme LLC | $52.82 | 2021-2025 | Steglujan, Steglatro, Belsomra |
| Novartis Pharmaceuticals Corporation | $39.84 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $39.22 | 2022 | |
| Dexcom, INC. | $34.66 | 2023-2025 | Dexcom G6 Transmitter |
| Lundbeck LLC | $34.49 | 2023 | Rexulti |
| Corcept Therapeutics | $26.96 | 2024 | Korlym |
| Gilead Sciences, INC. | $26.17 | 2025 | |
| Allergan, INC. | $25.22 | 2020 | |
| Sanofi-Aventis U.S. LLC | $23.50 | 2025 | |
| Vifor Pharma, INC. | $23.08 | 2022 | |
| Eisai INC. | $22.28 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.29 | 2022 | |
| Biogen, INC. | $18.27 | 2021 | |
| Paratek Pharmaceuticals, INC. | $16.62 | 2024 | Nuzyra |
| Horizon Therapeutics Plc | $16.09 | 2022 | |
| Smith+Nephew, INC. | $16.09 | 2025 | Collagenase Santyl |
| Kowa Pharmaceuticals America, INC. | $13.90 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Ahmed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.